However, there remains a considerable lack of data related to LAG-3 or TIM-3 expression in DLBCL, as well as other tumors, despite a number of clinical trials for anti-LAG-3 or anti-TIM-3 therapies (as single agent or combinations) in solid tumors and hematologic malignancies. This evidence concerns the gene LAG3 and hematologic disorder.